Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1)

Research output: Contribution to journalArticle

Abstract

Agelastatins are a family of tetracyclic alkaloids isolated from marine sponges. The patent examined in this publication covers the chemical synthesis of agelastatins A to F and eight analogues and their therapeutic use against hematologic malignancies. The claim on the chemical synthesis features a novel biomimetic cyclization of a tricyclic precursor, which streamlines scalable access to agelastatins and their analogues. This new synthetic approach can potentially expedite the research on these compounds for therapeutic use against cancers by making them more easily available. The claim on the therapeutic use against hematologic malignancies is based on the in vitro cytotoxicity against a limited number of cell lines and can be further strengthened by in vivo therapeutic evaluations focusing on specific hematologic malignancies. The comparative evaluation of the cytotoxicities of the natural alkaloids described in the application greatly enhances the understanding of their structure-activity relationships (SARs) relevant to the development of novel medicinal leads. Overall, the patent application is strong and has the potential to advance the rapidly expanding agelastatin research.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Volume27
Issue number2
DOIs
Publication statusPublished - Feb 1 2017
Externally publishedYes

Fingerprint

Therapeutic Uses
Hematologic Neoplasms
Alkaloids
Biomimetics
Porifera
Cyclization
Structure-Activity Relationship
Research
Cell Line
Neoplasms
Therapeutics

Keywords

  • Agelastatin alkaloid
  • apoptosis
  • blood cancer
  • chemical synthesis
  • cytotoxicity

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Compounds, compositions, and methods of agelastatin alkaloids : patent evaluation of WO2015042239 (A1). / Yoshimitsu, Takehiko; Tun, Han W.

In: Expert Opinion on Therapeutic Patents, Vol. 27, No. 2, 01.02.2017, p. 113-119.

Research output: Contribution to journalArticle

@article{68eae6dd4f7045048a7a9fa785580be5,
title = "Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1)",
abstract = "Agelastatins are a family of tetracyclic alkaloids isolated from marine sponges. The patent examined in this publication covers the chemical synthesis of agelastatins A to F and eight analogues and their therapeutic use against hematologic malignancies. The claim on the chemical synthesis features a novel biomimetic cyclization of a tricyclic precursor, which streamlines scalable access to agelastatins and their analogues. This new synthetic approach can potentially expedite the research on these compounds for therapeutic use against cancers by making them more easily available. The claim on the therapeutic use against hematologic malignancies is based on the in vitro cytotoxicity against a limited number of cell lines and can be further strengthened by in vivo therapeutic evaluations focusing on specific hematologic malignancies. The comparative evaluation of the cytotoxicities of the natural alkaloids described in the application greatly enhances the understanding of their structure-activity relationships (SARs) relevant to the development of novel medicinal leads. Overall, the patent application is strong and has the potential to advance the rapidly expanding agelastatin research.",
keywords = "Agelastatin alkaloid, apoptosis, blood cancer, chemical synthesis, cytotoxicity",
author = "Takehiko Yoshimitsu and Tun, {Han W.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/13543776.2017.1273902",
language = "English",
volume = "27",
pages = "113--119",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Compounds, compositions, and methods of agelastatin alkaloids

T2 - patent evaluation of WO2015042239 (A1)

AU - Yoshimitsu, Takehiko

AU - Tun, Han W.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Agelastatins are a family of tetracyclic alkaloids isolated from marine sponges. The patent examined in this publication covers the chemical synthesis of agelastatins A to F and eight analogues and their therapeutic use against hematologic malignancies. The claim on the chemical synthesis features a novel biomimetic cyclization of a tricyclic precursor, which streamlines scalable access to agelastatins and their analogues. This new synthetic approach can potentially expedite the research on these compounds for therapeutic use against cancers by making them more easily available. The claim on the therapeutic use against hematologic malignancies is based on the in vitro cytotoxicity against a limited number of cell lines and can be further strengthened by in vivo therapeutic evaluations focusing on specific hematologic malignancies. The comparative evaluation of the cytotoxicities of the natural alkaloids described in the application greatly enhances the understanding of their structure-activity relationships (SARs) relevant to the development of novel medicinal leads. Overall, the patent application is strong and has the potential to advance the rapidly expanding agelastatin research.

AB - Agelastatins are a family of tetracyclic alkaloids isolated from marine sponges. The patent examined in this publication covers the chemical synthesis of agelastatins A to F and eight analogues and their therapeutic use against hematologic malignancies. The claim on the chemical synthesis features a novel biomimetic cyclization of a tricyclic precursor, which streamlines scalable access to agelastatins and their analogues. This new synthetic approach can potentially expedite the research on these compounds for therapeutic use against cancers by making them more easily available. The claim on the therapeutic use against hematologic malignancies is based on the in vitro cytotoxicity against a limited number of cell lines and can be further strengthened by in vivo therapeutic evaluations focusing on specific hematologic malignancies. The comparative evaluation of the cytotoxicities of the natural alkaloids described in the application greatly enhances the understanding of their structure-activity relationships (SARs) relevant to the development of novel medicinal leads. Overall, the patent application is strong and has the potential to advance the rapidly expanding agelastatin research.

KW - Agelastatin alkaloid

KW - apoptosis

KW - blood cancer

KW - chemical synthesis

KW - cytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85008414310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008414310&partnerID=8YFLogxK

U2 - 10.1080/13543776.2017.1273902

DO - 10.1080/13543776.2017.1273902

M3 - Article

C2 - 28056571

AN - SCOPUS:85008414310

VL - 27

SP - 113

EP - 119

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 2

ER -